Ipsen S.A. (LON:0MH6)

London flag London · Delayed Price · Currency is GBP · Price in EUR
138.80
-1.00 (-0.72%)
At close: Feb 11, 2026
Market Cap9.91B +20.2%
Revenue (ttm)3.22B +11.5%
Net Income383.94M -32.4%
EPS4.60 -32.3%
Shares Outn/a
PE Ratio25.81
Forward PE11.57
Dividend1.18 (0.87%)
Ex-Dividend DateJun 4, 2025
Volume775
Average Volume9,559
Open140.00
Previous Close139.80
Day's Range137.80 - 142.60
52-Week Range88.05 - 139.90
Beta0.27
RSI67.24
Earnings DateFeb 12, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i... [Read more]

Industry Pharmaceutical Preparations
Founded 1929
Employees 5,358
Stock Exchange London Stock Exchange
Ticker Symbol 0MH6
Full Company Profile

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.

Financial numbers in EUR Financial Statements